文献速递肝病

核内miR-204-3p减轻小鼠代谢功能障碍相关脂肪性肝病

se in mice.Nuclear miR-204-3p mitigates metabolic dysfunction-associated steatotic liver disea.
PubMed 文献 · J Hepatol · 2024-02-06

该研究在MASLD患者和小鼠中探究miR-204-3p对脂肪性肝炎的作用。患者外周血单个核细胞miR-204-3p水平与肝炎症和损伤严重程度负相关;巨噬细胞特异性过表达miR-204-3p可减轻高脂或MCD饮食小鼠的脂肪性肝炎,机制涉及抑制TLR4/JNK信号和激活ULK1转录改善自噬流。

要点

  • MASLD患者PBMC中miR-204-3p水平与肝炎症和损伤严重程度呈负相关
  • 巨噬细胞miR-204-3p过表达减轻小鼠脂肪性肝炎
  • 核内miR-204-3p通过激活ULK1转录和改善自噬流抑制巨噬细胞炎症

核心结论

  • miR-204-3p抑制巨噬细胞炎症,协调巨噬细胞对肝细胞和HSC的作用,改善脂肪性肝炎。
  • 巨噬细胞miR-204-3p可能是MASLD的治疗靶点。

研究设计与样本

  • 检测MASLD患者肝脏和外周血单个核细胞中miR-204-3p水平及亚细胞定位。
  • 高脂或蛋氨酸胆碱缺乏饮食喂养的野生型小鼠注射含miR-204-3p的腺相关病毒系统。
  • 采用共培养体系研究巨噬细胞与肝细胞或肝星状细胞(HSC)的交互作用。
  • 进行多种高通量表观基因组测序探索miR-204-3p靶点。

主要发现

  • miR-204-3p在小鼠和脂肪肝患者的肝脏及巨噬细胞中表达降低。
  • MASLD患者外周血单个核细胞中miR-204-3p水平与肝炎症和损伤严重程度呈负相关。
  • 巨噬细胞特异性miR-204-3p过表达减轻高脂或MCD饮食喂养小鼠的脂肪性肝炎。
  • 过表达miR-204-3p的巨噬细胞抑制TLR4/JNK信号和促炎细胞因子释放,限制肝细胞脂肪沉积和炎症以及HSC纤维化活化。
  • 表观基因组分析鉴定miR-204-3p为ULK1表达的特异性调节因子;核内miR-204-3p激活ULK1转录和VPS34复合物,改善自噬流。

临床怎么用

  • MASLD患者外周血单个核细胞miR-204-3p水平与肝炎症和损伤严重程度负相关,可能作为疾病严重程度的候选生物标志物。
  • 靶向巨噬细胞miR-204-3p可能是MASLD的潜在治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Accumulating evidence has indicated the presence of mature microRNAs (miR) in the nucleus, but their effects on steatohepatitis remain elusive. We have previously demonstrated that the intranuclear miR-204-3p in macrophages protects against atherosclerosis, which shares multiple risk factors with metabolic dysfunction-associated steatotic liver disease (MASLD). Herein, we aimed to explore the functional significance of miR-204-3p in steatohepatitis. METHODS: miR-204-3p levels and subcellular localization were assessed in the livers and peripheral blood mononuclear cells of patients with MASLD. Wild-type mice fed high-fat or methionine- and choline-deficient diets were injected with an adeno-associated virus system containing miR-204-3p to determine the effect of miR-204-3p on steatohepatitis. Co-culture systems were applied to investigate the crosstalk between macrophages and hepatocytes or hepatic stellate cells (HSCs). Multiple high-throughput epigenomic sequencings were performed to explore miR-204-3p targets. RESULTS: miR-204-3p expression decreased in livers and macrophages in mice and patients with fatty liver. In patients with MASLD, miR-204-3p levels in peripheral blood mononuclear cells were inversely related to the severity of hepatic inflammation and damage. Macrophage-specific miR-204-3p overexpression reduced steatohepatitis in high-fat or methionine- and choline-deficient diet-fed mice. miR-204-3p-overexpressing macrophages inhibited TLR4/JNK signaling and pro-inflammatory cytokine release, thereby limiting fat deposition and inflammation in hepatocytes and fibrogenic activation in HSCs. Epigenomic profiling identified miR-204-3p as a specific regulator of ULK1 expression. ULK1 transcription and VPS34 complex activation by intranuclear miR-204-3p improved autophagic flux, promoting the anti-inflammatory effects of miR-204-3p in macrophages. CONCLUSIONS: miR-204-3p inhibits macrophage inflammation, coordinating macrophage actions on hepatocytes and HSCs to ameliorate steatohepatitis. Macrophage miR-204-3p may be a therapeutic target for MASLD. IMPACT AND IMPLICATIONS: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a chronic inflammatory disease ranging from simple steatosis to steatohepatitis. However, the molecular mechanisms underlying the progression of MASLD remain incompletely understood. Here, we demonstrate that miR-204-3p levels in circulating peripheral blood mononuclear cells are negatively correlated with disease severity in patients with MASLD. Nuclear miR-204-3p activates ULK1 transcription and improves autophagic flux, limiting macrophage activation and hepatic steatosis. Our study provides a novel understanding of the mechanism of macrophage autophagy and inflammation in steatohepatitis and suggests that miR-204-3p may act as a potential therapeutic target for MASLD.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Zou Z, Liu X, Yu J, et al. se in mice.Nuclear miR-204-3p mitigates metabolic dysfunction-associated steatotic liver disea. J Hepatol. 2024. PMID: 38331323. doi:10.1016/j.jhep.2024.01.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。